Neurizon Therapeutics has reported a positive interim eight-month update on its ongoing 12-month open-label extension (OLE) ...

Its lead product is NeuroNata-R (lenzumestrocel ... assess the safety and efficacy of NeuroNata-R in more than 94 patients with ALS. Patients will be randomized to receive two doses of study ...

MaaT033, an experimental oral therapy for improving gut microbiome health, was shown to be safe and well tolerated in ALS ...

Methodology This is an observational cohort study, using the clinical database from the Olesoxime (TRO19622) investigational medicinal product trial. This trial involving 512 patients with ALS was ...

A potential new treatment for neurological disease ALS has shown promising results after being tested on its first patient ALS is notoriously difficult to treat, with most patients dying three to five ...

Results showed that NUZ-001 worked in a unique way to stop the aggregation of TDP-43, a protein that builds up in patients with ALS and contributes to disease progression. Normally TDP-43 is ...

Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by ...